4.16
-0.12(-2.80%)
Currency In USD
| Previous Close | 4.28 |
| Open | 4.31 |
| Day High | 4.35 |
| Day Low | 4.04 |
| 52-Week High | 6.94 |
| 52-Week Low | 1.11 |
| Volume | 3.08M |
| Average Volume | 3.83M |
| Market Cap | 736.33M |
| PE | -2.93 |
| EPS | -1.42 |
| Moving Average 50 Days | 3.83 |
| Moving Average 200 Days | 3.37 |
| Change | -0.12 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $270.66 as of January 14, 2026 at a share price of $4.16. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 3 years ago, it would be worth $261.47 as of January 14, 2026 at a share price of $4.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chie
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
GlobeNewswire Inc.
Dec 07, 2025 1:05 PM GMT
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chie